Objective
to report the clinical efficacy of SVELTE SES system compared with Xience or Promus EES for the treatment of coronary artery obstructions
Study
multicentre, randomised non-inferiority trial (3.58% margin)
Population
patients with non-STEMI or stable CAD
Endpoints
target lesion failure as cardiac death, MI or clinically indicated target lesion revascularisation at 12 months
Conclusion
SVELTE â SES did not meet the prespecified threshold for non- inferiority compared to EES at 1 year
Kereiakes et al. Circulation Cardiovascular Interventions. 2021;14:e010609
